Medicine and Dentistry
Haemophilia A
100%
Pulmonary Embolism
84%
Bleeding
73%
Von Willebrand Disease
55%
Desmopressin
50%
COVID-19
45%
Bleeding Disorder
44%
Systematic Review
40%
Acute Pulmonary Embolism
34%
Vitamin K Antagonist
34%
Von Willebrand Factor
33%
D-Dimer
32%
Blood Clotting Factor 8
30%
Thrombosis
29%
Venous Thromboembolism
24%
Randomized Controlled Trial
24%
COVID-19 Vaccination
23%
Pharmacokinetics
23%
Major Bleeding
19%
Anticoagulation
18%
Meta-Analysis
17%
Thrombotic Thrombocytopenic Purpura
17%
Quality of Life
17%
Cross Sectional Study
16%
Diseases
16%
Ciclonicate
15%
Thromboembolism
15%
Platelet
14%
Lochia
13%
Prevalence
13%
Pulmonary Angiography
13%
Antiplatelet
13%
Patient-Reported Outcome
12%
Atrial Fibrillation
12%
Cohort Analysis
12%
Odds Ratio
12%
Blood Clotting Factor 8 Concentrate
12%
Platelet Disorder
12%
Post-Hoc Analysis
11%
Direct Oral Anticoagulant
11%
Outcome Assessment
11%
Proteomics
11%
Deep Vein Thrombosis
11%
Blood Stasis
11%
Intensive Care Unit
11%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Thrombocyte Function
9%
Health Care Cost
9%
Hemarthrosis
9%
Anticoagulant Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Haemophilia A
57%
Bleeding
52%
Lung Embolism
50%
Pharmacokinetics
48%
Diseases
44%
Von Willebrand Disease
44%
Antivitamin K
41%
Desmopressin
41%
Von Willebrand Factor
40%
Anticoagulant Agent
34%
Coronavirinae
34%
Venous Thromboembolism
31%
Thrombosis
30%
Randomized Controlled Trial
30%
D Dimer
22%
Cohort Study
21%
Blood Clotting Factor 8
20%
Malignant Neoplasm
19%
Bleeding Disorder
14%
Low Molecular Weight Heparin
13%
Antiplatelet
13%
Atrial Fibrillation
12%
Blood Clotting Factor Concentrate
12%
Thrombotic Thrombocytopenic Purpura
12%
Ciclonicate
11%
Nadroparin
11%
Antithrombotic Therapy
11%
Thromboembolism
11%
Blood Clotting Factor 8 Concentrate
10%
Thrombocytopenia
10%
Thrombocyte Factor 4
8%
Vitamin K Group
8%
Vein Thrombosis
7%
Postpartum Hemorrhage
7%
Procoagulant
7%
Replacement Therapy
7%
Messenger RNA
6%
Antiphospholipid Antibody
6%
Blood Clotting Factor 10a Inhibitor
6%
Prospective Cohort Study
6%
Menorrhagia
6%
Cardiovascular Disease
6%
Blood Stasis
6%
Retinol
6%
Pharmacodynamics
6%
Fibrinogen
6%
Thrombin
5%
Overall Survival
5%
Breast Cancer
5%
Phospholipid
5%
Nursing and Health Professions
Haemophilia A
28%
Anticoagulant Agent
28%
Lung Embolism
24%
Diseases
17%
Desmopressin
17%
Home Care
13%
Bleeding
13%
Deprescribing
12%
Confidence Interval
12%
Post Hoc Analysis
11%
Von Willebrand Disease
11%
Perioperative
11%
Patient-Reported Outcome
11%
Thrombosis
11%
Outcome Assessment
11%
Information Systems
11%
Terminal Care
11%
Intensive Care Unit
10%
Quality of Life
8%
Malignant Neoplasm
8%
Odds Ratio
7%
Cohort Analysis
7%
Clinical Practice
7%
Blood Clotting Factor 8
7%
Bleeding Disorder
6%
Venous Thromboembolism
6%
Blood Clotting Factor Concentrate
6%
Von Willebrand Factor
6%
Lupus Anticoagulant
5%
Tachyphylaxis
5%
Outpatient
5%
Psychometry
5%
Thrombocyte Disorder
5%
Postthrombosis Syndrome
5%
Reproducibility
5%
Deterioration
5%
Cost Benefit Analysis
5%
Prevalence
5%
Idiopathic Thrombocytopenic Purpura
5%
Overall Survival
5%
Clinical Decision Support System
5%
Health Care Cost
5%
Lung Angiography
5%
